Advertisement
MCT First Disclosures

Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity

Helen Kotanides, Rose Marie Sattler, Maria B. Lebron, Carmine Carpenito, Juqun Shen, Jingxing Li, David Surguladze, Jaafar N. Haidar, Colleen Burns, Leyi Shen, Ivan Inigo, Anthony L. Pennello, Amelie Forest, Xinlei Chen, Darin Chin, Andreas Sonyi, Michael Topper, Lauren Boucher, Prachi Sharma, Yiwei Zhang, Douglas Burtrum, Ruslan D. Novosiadly, Dale L. Ludwig, Gregory D. Plowman and Michael Kalos
DOI: 10.1158/1535-7163.MCT-19-0893 Published April 2020

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: March 2020 to January 2021

AbstractFull-text HTMLPDF
Total23151428705

Cited By

Article Information

Volume 19, Issue 4, pp. 988-998

DOI 
https://doi.org/10.1158/1535-7163.MCT-19-0893
PubMed 
32241872
Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • Received September 15, 2019
  • Revision received December 17, 2019
  • Accepted February 10, 2020
  • Published first April 2, 2020.
Copyright & Usage 
©2020 American Association for Cancer Research.

Author Information

  1. Helen Kotanides*,
  2. Rose Marie Sattler,
  3. Maria B. Lebron,
  4. Carmine Carpenito,
  5. Juqun Shen,
  6. Jingxing Li,
  7. David Surguladze,
  8. Jaafar N. Haidar,
  9. Colleen Burns,
  10. Leyi Shen,
  11. Ivan Inigo,
  12. Anthony L. Pennello,
  13. Amelie Forest,
  14. Xinlei Chen,
  15. Darin Chin,
  16. Andreas Sonyi,
  17. Michael Topper,
  18. Lauren Boucher,
  19. Prachi Sharma,
  20. Yiwei Zhang,
  21. Douglas Burtrum,
  22. Ruslan D. Novosiadly,
  23. Dale L. Ludwig,
  24. Gregory D. Plowman, and
  25. Michael Kalos
  1. Lilly Research Laboratories, Eli Lilly and Company, New York, New York.
  1. ↵*Corresponding Author:
    Helen Kotanides, Eli Lilly and Company, 450 East 29th Street, 12th Floor, New York, NY 10016. Phone: 646-638-5017; E-mail: helen.kotanides{at}lilly.com

  • Current address for P. Sharma: Regeneron Pharmaceuticals, Tarrytown, NY; current address for R.D. Novosiadly: Bristol-Myers Squibb, Princeton, NJ; current address for D.L. Ludwig: Actinium Pharmaceuticals, New York, NY; and current address for M. Kalos: Arsenal Biosciences, San Francisco, CA.

View Full Text
Back to top
View this article with LENS

Open full page PDF
Article Alerts
Email Article
Citation Tools
Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
Helen Kotanides, Rose Marie Sattler, Maria B. Lebron, Carmine Carpenito, Juqun Shen, Jingxing Li, David Surguladze, Jaafar N. Haidar, Colleen Burns, Leyi Shen, Ivan Inigo, Anthony L. Pennello, Amelie Forest, Xinlei Chen, Darin Chin, Andreas Sonyi, Michael Topper, Lauren Boucher, Prachi Sharma, Yiwei Zhang, Douglas Burtrum, Ruslan D. Novosiadly, Dale L. Ludwig, Gregory D. Plowman and Michael Kalos
Mol Cancer Ther April 1 2020 (19) (4) 988-998; DOI: 10.1158/1535-7163.MCT-19-0893
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement